Leading five pharmaceutical firms accounts for 60 percent in R&D investment

Published: 2002-07-12 06:59:00

Updated: 2002-07-12 06:59:00

The combined turnover of the domestic pharmaceutical firms closing their fiscal year at December, including 37 KOSDAQ-listed pharmaceutical firms in 2001, marked an average growth rate of 9.8 percent, to 3.17 trillion won compared with the same period of the previous year, while R&D expenditures ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK